CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. (CBLL) reported third-quarter 2026 revenue of $29.341 million, up 30% from $22.589 million a year earlier. Product revenue was $22.235 million and subscription revenue was $7.106 million. Gross margin was 90%, compared with 88%, while operating expenses increased 36% to $46.888 million. Net loss was $21.351 million, compared with $13.465 million, and adjusted EBITDA loss, a non-GAAP measure, was $12.140 million versus $9.230 million.
At quarter-end, Ceribell had 747 active accounts and added 35 net new customers; same-store utilization grew by double digits. The company received FDA 510(k) clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis and fully launched its delirium monitoring solution after a commercial pilot. Cash, cash equivalents and marketable securities totaled $117.5 million as of September 30, 2026. An August credit facility provides access to up to $60 million in committed capital and an additional $25 million in uncommitted capital at the lender’s discretion. Full-year 2026 revenue guidance was raised to $115 million to $117 million, representing approximately 29% to 31% growth over 2025 revenue; the range excludes material contributions from neonate, pediatric or delirium products.
Ceribell, Inc. officer Raymond Woo is identified in a notice covering the proposed sale of 4,887 common shares, with an aggregate market value of $131,753.52 and an approximate sale date of November 2, 2026. The notice lists a stock option exercise from the issuer for cash, dated November 2, 2026, for 4,887 shares. It also reports prior sales by Woo: 1,979 shares on August 21, 2026; 4,887 on September 8, 2026; and 4,887 on October 1, 2026.
Ceribell, Inc. Chief Technology Officer Raymond Woo exercised options on October 1, 2026, to acquire 4,864 shares at $3.65 per share and 23 shares at $4.70 per share, and sold 4,887 shares at $24.38 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan Raymond Woo adopted on June 5, 2026.
Ceribell, Inc. officer Raymond Woo listed 4,887 common shares for sale through Fidelity Brokerage Services LLC, with an approximate aggregate market value of $119,145.06 and a sale date of October 1, 2026. An October 1 stock-option exercise for 4,887 shares, with cash payment, is also listed.
For the preceding three months, Woo listed sales of 1,979 shares for $47,539.14 on August 21, 2026, and 4,887 shares for $118,900.71 on September 8, 2026.
Ceribell, Inc. (CBLL) director, President and CEO Chao Xingjuan reported selling 20,846 shares of common stock on September 15, 2026 at a weighted average price of $25.03 per share under a Rule 10b5-1 trading plan adopted September 12, 2025. Following this sale, she holds 746,345 shares directly and 369,088 shares indirectly through the ACP 2021 Trust, for which she is a co-trustee and disclaims beneficial ownership except for her pecuniary interest.
Ceribell, Inc. (CBLL) reported that its Chief Financial Officer, Scott Blumberg, exercised stock options for 846 shares of common stock at an exercise price of $9.41 per share on September 15, 2026, and sold 846 shares of common stock at a weighted average price of about $25 per share the same day. These transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following the option exercise, he held 51,802 stock options that are fully vested and currently exercisable.
Ceribell, Inc. (CBLL) received a notice under Rule 144 that officer Scott E. Blumberg, through Fidelity Brokerage Services LLC, intends to sell 846 shares of Ceribell common stock, with an aggregate market value of $21,150.81, around September 15, 2026 on NASDAQ.
The notice states that 38,378,101 shares of Ceribell common stock were outstanding. The shares to be sold are tied to a stock options exercise for cash. The filing also lists prior sales by Scott E. Blumberg over the past three months.
Ceribell, Inc. (CBLL) officer and director Xingjuan Chao reported a proposed sale of 20,846 common shares, with an aggregate market value of $521,773.40 and an approximate sale date of September 15, 2026. The notice lists a Rule 10b5-1 plan adoption date of September 12, 2025. Chao acquired the shares through a cash-paid stock option exercise from the issuer on April 30, 2018. The past-three-month sales table also lists a sale of 39,540 shares on September 2, 2026, for gross proceeds of $973,089.52.
Ceribell, Inc. insider David Foehr, Senior VP, Finance and PAO, exercised options for 7,500 shares of common stock at $4.70 per share on September 8, 2026, and on the same date sold a total of 9,255 shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
After the option exercise, he reported 45,385 option-based rights remaining; his common-stock holdings after the sales were not stated.
Ceribell, Inc. (CBLL) reported that Chief Technology Officer Raymond Woo exercised stock options to acquire a total of 13,276 shares of common stock on September 8, 2026, at exercise prices of $2.24, $3.65, and $4.70 per share, and sold 4,887 shares of common stock at $24.33 per share the same day. The company states these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Woo on June 5, 2026.